Vaccine World Summit India 2013

Into its 3rd year of running, Vaccine World Summit India continues to provide an unrivaled meeting platform in Pune, India from 5-7 March 2013 for leading vaccine industry players to explore partnership opportunities at various stages of the vaccine lifecycle, from the earliest basic research, extends through licensure to all dimensions of the vaccine production.

This summit will be taking place at the Westin Pune Koregaon Park.

Conference speakers include:

    Dr Suresh Jadhav ,

    Executive Director,

    Serum Institute, India

    Dr Rajiv Indravadan Modi,

    Director/Managing Director,

    Cadila Pharmaceuticals, India

    Dr Inderjit Singh Sarao,

    Associate Director,

    Merck, USA

    Dr James F. Young,

    Chairman,

    Novavax, USA

    Dr Harish Iyer Dr Harish Iyer,

    CEO,

    Shantha Biotechnics, India

    Dr Norman Baylor,

    Advisor,

    PATH MVI Vaccine Science Portfolio Advisory Council (VSPAC), USA

    Dr Ranga Iyer,

    Advisor,

    Indian Health Progress & Global Pharma Associations, India

    Dr Raj Shankar Ghosh,

    Technical Director,

    PATH , India

    Dr Stanley Erck,

    President and CEO,

    Novavax, USA

    Dr Anand Kumar,

    Deputy Managing Director,

    Indian Immunologicals, India

    Dr V. Krishna Mohan,

    Executive Director,

    Bharat Biotech International, India

    Dr SD Ravetkar,

    Executive Director,

    Serum Institute, India

    Dr Reinhard Glueck,

    Chief Scientific Officer,

    Zydus Cadila, India

    Dr Shirshendu Mukherjee,

    Senior Strategic Advisor,

    Wellcome Trust, India

    Dr Davinder Gill,

    Chief Executive Officer,

    MSD Wellcome Trust Hilleman Laboratories, India

    Dr Ramesh S. Paranjape,

    Director,

    National AIDS Research Institute, India

    Dr Vipin Dr Vipin Vashishtha,

    Convener,

    Indian Academy of Pediatrics - Committee on Immunization, India

    Helen YangHelen Yang,

    Business Development Director,

    Sinovac Biotech, China

    Dr Sanjay Singh,

    Chairman,

    Gennova Biopharma, India

    Dr Jacqui Shea,

    General Manager,

    Oxford-Emergent Tuberculosis Consortium, UK

    Abdul Muktadir,

    Managing Director,

    Incepta, Bangladesh

    Mr Abdul Muktadir is the Managing Director of Incepta Vaccine Ltd and Incepta Pharmaceuticals Ltd, the 2nd largest Pharmaceuticals Company in Bangladesh. Since its introduction in 1999, Incepta achieved highest growth among all pharmaceuticals companies which is remarkable not only for Bangladesh but also for south-east Asia. He is also the Secretary General of “Bangladesh Association of Pharmaceuticals Industries” which is the official association of all the pharmaceutical companies in the country. He is well known as one of the most experienced & technically knowledgeable entrepreneurs in the Pharmaceutical sector. Now Mr Muktadir has dedicated himself in developing vaccine facility in Bangladesh for the first time. He intends to develop all conventional vaccines at affordable costs. Incepta is also exploring a number of new technologies from various partners to introduce new vaccines for developing countries.  He was born 06 May 1957 at Magura, a western District of Bangladesh. He completed his B.Pharm (Hons.) & M.Pharm (Thesis) from University of Dhaka. Then he went to USA and completed his M.S. in Industrial Pharmacy in 1984 from Long Island University, New York. His Research areas were Anti-tumor antibiotic in University of Dhaka & IPGMR (BSMMU) and Dosage Form Design in Long Island University, USA. He has Special research interest in Aerosol, Nanotechnology, Sustain release drug, Special Drug Delivery Systems, Design of Pharmaceutical Factory etc. He spent from 1985-1999 at Beximco Pharmaceuticals Ltd in various positions and finally left as Director Operations. Since late 1999, Mr. Abdul Muktadir has been steering Incepta in to new areas of businesses to eventually make it a global source of generic drugs, vaccines and other healthcare products.

    Dr Rajendra JaniDr Rajendra Jani,

    Senior Vice President of Clinical R&D,

    Cadila Healthcare, India

    Dr Rajendra Jani has earned doctorate in pathology and bacteriology from faculty of medicine under the guidance of renowned pathologists; Professor Roy, Government Medical College, Surat and Professor J. G. Collee from faculty of medicine, University of Edinburg, United Kingdom. He has contributed in about 100 patents and published number of research papers. He has conceptualized and conducted 22 “first in man” (phase 1) studies, where new chemical / biological entities and vaccines were first time administered to human being, and more than 120 clinical studies from phase 1-4. Dr Rajendra Jani has more than 30 years’ experience in drug research and has worked as an Assistant Professor at Government Medical College, Surat and also with research driven companies such as Cynamid, Hoechst, Rhone-Poulenc, German Remedies Limited and its affiliates Boehringer Ingelheim, Schering AG, ASTA Medical, etc., in various capacities. Dr Rajendra Jani is Senior Vice President and Head of Clinical R&D, Cadila Healthcare Limited, a flagship company of Zydus group. The company has fully integrated in-house clinical research facility. He is responsible for strategies and execution of GCP compliant Phase I-IV clinical development programs of the company. Recently Zydus Cadila has completed Phase 1 to phase 3 studies with ZYH1, a new anti-dyslipidemic drug under his leadership.

    Dr Gregory Glenn,

    Senior VP and CMO,

    Novovax

    Dr. Glenn is a pioneer in vaccine delivery and adjuvants, and has brought several products from concept into clinical development, such as the travelers'' diarrhea vaccine patch and an adjuvant patch for a pandemic influenza vaccine, developed under U.S. government contracts. He provided the scientific and technical leadership that led to the acquisition of IOMAI by Intercell in 2008. He has co-authored more than 150 research publications, scientific abstracts and presentations, and successful grant applications, and holds multiple U.S., European and other international patents. In addition, he is an associate editor of the journals Expert Review of Vaccines, and Human Vaccine, and was a board-certified pediatrician. Dr. Glenn received his Bachelor of Arts degree in Biology and Chemistry from Whitman College and his Doctor of Medicine degree from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.

    Ashish Dr Ashish Bavdekar,

    President,

    IAP - Gastroenterology Chapter

    Dr. Ashish Bavdekar completed his medical studies from B.J. Medical College and K.E.M. Hospital, Pune. He subsequently received training at Sheffield Children''s Hospital, Sheffield, UK.  He is the President of the Indian Academy of Pediatrics (IAP) – Gastroenterology Chapter. He has been on several IAP task force - Neonatal Cholestasis, Safe Injection Practices, Childhood Obesity and Acute Diarrhoea. He has special research interests in metabolic liver diseases, clinical nutrition and human gut flora. Dr. Bavdekar was and is currently involved in many clinical vaccine and drug trials as an investigator – The  Measles Aerosol Vaccine project, Meningoccal Vaccine Project, safety and immunogenicity studies on HPV, rotavirus, live attenuated hepatitis A, hepatitis B, H1N1, 13 valent pneumococcal, conjugate typhoid and other vaccines, probiotics in diarrhea, enzyme replacement therapy in Gaucher’s disease, etc. He is now actively involved with the phase III efficacy study of an indigenous rotavirus vaccine.

    Ashish Kenneth Kelley,

    Co-Founder, CEO, Executive Chairman,

    PaxVax

    Prof T Jacob John,

    Virologist,

    Christian Medical College in Vellore,

    WHO

    Committee

    Global Polio Eradication, India

   

    Dr Shailesh Mehta,

    Medical Director of Clinical R&D (Medical Affairs Biologics - South Asia),

    GSK

    Dr Ramesh Matur,

    General Manager of R&D,

    Indian Immunologicals

    Dr Sudhakar Konda,

    Vice President,

    One Stream R&D (Panacea)

    Dr Steve Whitehead,

    Head of Dengue Project,

    Laboratory of Infectious Diseases of NIH

    Dr Subhra Chakrabarti,

    Head of Manufacturing Technology,

    Shantha Biotechnics

    Dr Rakesh Sinha,

    General Manager and Project Director of JE Vaccine,

    Biological E.

    Dr Nathelie Garcon,

    Vice President and Head of Global Adjuvant Centre for Vaccine Development,

    GSK Biologicals

    Dr Anuj Walia,

    Regional Director of Medical Affairs,

    MSD Pharmaceuticals

    Dr Alfred Luitjens,

    Early Stage Development Leader for the Inactivated Polio Project and Senior Scientist,

    Crucell

Early bird closing 31 January 2013!